Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older
NCT05639894
Completed
Brief Summary of Stage 1: The purpose Stage 1 (Phase I/IIa) is to assess the safety and immunogenicity of a single intramuscular (IM) injection of 3 dose-levels of an Respiratory Syncytial Virus (RSV) vaccine candidate formulated with 2 different lipid nanoparticles (LNPs) in healthy adult participants aged between 18 to 50 years, and 60 years and older. The primary objectives of this stage are to assess the safety and immunogenicity profiles across the dose-level groups (low, medium, and high... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: Optimal Research Alabama Site Number : 8400032, Huntsville, Alabama +32 locations
Conditions: Respiratory Syncytial Virus Immunization
Register for Updates
A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older
NCT06744205
Active Not Recruiting
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular injection of different formulations of a hexavalent influenza messenger ribonucleic acid (mRNA) vaccine composed of differing dose levels of trivalent (TIV) mRNA hemagglutinin (HA) in combination with TIV mRNA-neuraminidase (NA) compared to an active control ((Fluzone standard-dose quadrivalent influenza vaccine (QIV-SD) or Fluzone high-dose quadrivalent influenza vaccine (QIV-HD) in adults 50 years... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/29/2025
Locations: Accel Research Sites Network - Birmingham- Site Number : 8400008, Birmingham, Alabama +23 locations
Conditions: Influenza, Healthy Volunteers
Register for Updates
COVID Protection After Transplant-Immunosuppression Reduction
NCT05077254
Completed
This study will enroll individuals who have: * Completed primary series of mRNA COVID-19 vaccine, and * An antibody response ≤ 2500 U/mL measured at least 30 days after the last dose of vaccine. This group of patients is at high risk for severe COVID-19 disease due to pharmacologic immunosuppression and a high prevalence of non-transplant risk factors such as obesity and diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: University of California, San Diego, San Diego, California +14 locations
Conditions: Kidney Transplant Recipients, Liver Transplant Recipients
Register for Updates
Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older
NCT06695130
Active Not Recruiting
Study VBT00002 is planned to be a Phase 1/2, randomized, modified double-blind, active-controlled, multi-center study to be conducted in approximately 980 adults aged 50 years and older in the United States. The purpose of the study is to assess the safety and immunogenicity of recombinant influenza vaccine (RIV) + adjuvanted recombinant COVID-19 vaccine (rC19) vaccine comprised of RIV combined with different recombinant Spike (rS) antigen levels of rC19 compared to RIV alone, rC19 (dose 1) alon... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/27/2025
Locations: Central Phoenix Medical Clinic- Site Number : 8400009, Phoenix, Arizona +11 locations
Conditions: COVID-19 Immunization, Influenza Immunization
Register for Updates
Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT02518555
Active Not Recruiting
This randomized phase II trial studies how well ibrutinib works when given together with vaccine therapies in treating patients without clinical signs or indications that raise the possibility of a particular disorder or dysfunction (asymptomatic) who have high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Vaccines, such as pneumococcal 13-valent conjugate vaccine, trivalent i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Register for Updates
IBRX-042 In Participants With HPV-Associated Tumors
NCT05976828
Recruiting
The goal of this clinical trial is to determine the maximum tolerated dose and to find out the side effects of a drug called IBRX-042 at different dose levels in patients with recurrent or progressive Human Papillomavirus (HPV) associated tumors. The main questions it aims to answer are: * What is the maximum tolerated dose of IBRX-042? * How well does the study drug treat cancer? * What effects the study drug may have on the human body and cancer? Participants will receive IBRX-042 at one of... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/22/2025
Locations: Chan Soon-Shiong Institute for Medicine (CSSIFM), El Segundo, California +2 locations
Conditions: HPV-Related Carcinoma
Register for Updates
A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older
NCT05071313
Completed
The purpose of this study is to evaluate the immunogenicity and safety of Ad26.RSV.preF-based vaccine and quadrivalent high-dose seasonal influenza vaccine when administered either concomitantly or separately.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
05/22/2025
Locations: Ark Clinical Research, Long Beach, California +18 locations
Conditions: Influenza, Human Prevention, Respiratory Syncytial Viruses Prevention
Register for Updates
Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting
NCT00622843
Completed
Purpose: To study the immune response of the newly licensed pneumococcal conjugate vaccine (PCV) in comparison to the pneumococcal polysaccharide vaccine (PPV) to determine if a significantly better immunologic response to boosting can be elicited in patients previously vaccinated with PPV.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
05/21/2025
Locations: Naval Medical Center San Diego, San Diego, California +5 locations
Conditions: HIV Infections, Streptococcus Pneumoniae
Register for Updates
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above
NCT06374394
Completed
This study will assess the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when it is co-administered with a COVID-19 messenger ribonucleic acid (mRNA) vaccine (Omicron XBB.1.5), compared to administration of the vaccines separately in adults aged 50 years and above.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/21/2025
Locations: GSK Investigational Site, Coral Gables, Florida +23 locations
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
NCT02111941
Completed
This pilot clinical trial studies the safety and immunogenicity of vaccine therapy in treating patients with stage IIIC-IV ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer following surgery and chemotherapy. Vaccines made from a person's peptide treated white blood cells may help the body build an effective immune response to kill tumor cells.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor, Fallopian Tube Mucinous Neoplasm, Fallopian Tube Serous Neoplasm, Fallopian Tube Transitional Cell Carcinoma, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Transitional Cell Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Undifferentiated Fallopian Tube Carcinoma, Undifferentiated Ovarian Carcinoma
Register for Updates
A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers
NCT02743455
Completed
This study is a multi-center, double-blind, placebo-controlled, Phase I study to evaluate the safety, reactogenicity, tolerability, and immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic-Yellow Fever (MVA-BN-YF) in Flavivirus-naive healthy male and non-pregnant female adult subjects. There are six dose groups in this study. Subjects who have never received a licensed or investigational smallpox vaccine will be randomized to Groups 1-5 and vaccine administration and follow-up will be cond... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
05/19/2025
Locations: University of Iowa - Vaccine Research and Education Unit, Iowa City, Iowa +1 locations
Conditions: Yellow Fever, Yellow Fever Immunisation
Register for Updates
A Double-Blind Placebo-Control Dose Escalating Study to Evaluate the Safety and Immunogenicity of dmLT by Oral, Sublingual and Intradermal Vaccination in Adults Residing in an Endemic Area
NCT03548064
Terminated
This is a trial to evaluate the safety and immunogenicity of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by oral, sublingual, or intradermal vaccination in approximately 135 healthy adult volunteers, age 18-45 years. Study duration is approximately 2.5 years, with each participant duration for up to 9 months depending on the route of dmLT administered. There is no specific hypothesis being tested in this study. The primary objective of this s... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
05/19/2025
Locations: University of Maryland, School of Medicine, Center for Vaccine Development and Global Health, Baltimore, Maryland +1 locations
Conditions: Gastroenteritis Escherichia Coli, Immunisation
Register for Updates